Green Journals

Year	A	B
2026	✓	✓
2025	✓	✓
2024	✓	✓
2023	✓	✓
2021/2022	✓	✓
2020	✓	✓
2019	✓	✓
2018	✓

Metabolic pathways as therapeutic target to improve allo-HSCT outcomes

Angimar Uriepero-Palma, Marie Krielle Tasha Pantino, Ratika Dogra et al.

2026-11-3

DOI: 10.1038/s41409-026-03071-0

Pre-transplant IFD history influences the incidence of IFD after allogeneic haematopoietic stem cell transplantation

Danping Zhu, Liyun Chen, Xiaoyu Zhu et al.

2026-10-30

DOI: 10.1038/s41409-026-03080-z

Long-term survival outcomes after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for relapsed/refractory metastatic germ cell tumors: contemporary Mayo Clinic experience

Saubia Fathima, Stephen M. Ansell, Patrick B. Johnston et al.

2026-10-29

DOI: 10.1038/s41409-026-03077-8

Clinical risk factors alone do not predict the development of moderate-severe chronic graft-versus-host disease after hematopoietic cell transplantation and post-transplant cyclophosphamide

Annie Im, Tao Wang, Zachariah DeFilipp et al.

2026-10-29

DOI: 10.1038/s41409-026-03082-x

Pre-transplant immunotherapy and MRD dynamics affect post-transplant prognosis in KMT2A-rearranged B-ALL patients

Shuangzhu Liu, Lejian Shi, Wenzhi Cai et al.

2026-10-28

DOI: 10.1038/s41409-026-03040-7

Lung transplantation after allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT

Juan Montoro, Saskia Bos, Christophe Peczynski et al.

2026-10-26

DOI: 10.1038/s41409-026-03079-6

The role of palliative and supportive care in haematopoietic cell transplantation and cellular therapy. Recommendations from the EBMT practice harmonisation and guidelines committee

Michelle Kenyon, Francesco Onida, Andrea Assanelli et al.

2026-10-26

DOI: 10.1038/s41409-026-03061-2

A multimodal approach to sexual function after allogeneic hematopoietic stem cell transplantation: a randomized controlled trial

Kristina Holmegaard Nørskov, Sofie Dorthea Andersen, Nicklas Lybaek et al.

2026-10-24

DOI: 10.1038/s41409-026-03075-w

How could calreticulin-targeting therapies change the myelofibrosis transplant paradigm?

Amy MacDonald, Isaac Gannon, Elena Torre et al.

2026-10-23

DOI: 10.1038/s41409-026-03060-3

Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

Jesús Duque-Afonso, Jürgen Finke, Allain-Thibeault Ferhat et al.

2026-10-23

DOI: 10.1038/s41409-026-03073-y

Journal Report

Journal Information

Classification History

Recent Articles